8-K: Treace Medical Reports Mixed 2025 Results, Forecasts 2026 Decline

Treace Medical Concepts reported full-year 2025 revenue growth of 2% to $212.7 million but saw a Q4 2025 revenue decrease of 9% and projects a 2026 revenue decline.

Summary

• Full-year 2025 revenue reached $212.7 million, an increase of 2% compared to $209.4 million in 2024.
• Fourth quarter 2025 revenue was $62.5 million, a decrease of 9% compared to $68.7 million in the fourth quarter of 2024, primarily driven by a shift in product sales toward lower-priced bunion kits.
• Full-year 2025 net loss was $(59.0) million, compared to a net loss of $(55.7) million in 2024.
• Fourth quarter 2025 net loss was $(9.4) million, compared to $(0.5) million for the same period in 2024.
• Full-year 2025 Adjusted EBITDA loss was reduced by 64% to $(3.9) million, compared to $(11.0) million in 2024.
• Fourth quarter 2025 Adjusted EBITDA was $6.2 million, compared to $11.1 million for the same period in 2024.
• Cash usage was reduced by 46% to $27.3 million in full-year 2025, compared to $50.5 million in full-year 2024.
• The company increased net new active surgeons by 202 for full-year 2025, ending the year with 3,337 active surgeons, a 6% increase.
• The global patent portfolio now totals 135 granted patents in addition to 199 pending patent applications.
• For full-year 2026, the company is initiating revenue guidance of $200 million to $212 million, representing a decline of 6% to 0% compared to full-year 2025.
• The company expects an Adjusted EBITDA loss in the range of $4.0 million to $6.0 million for full-year 2026, compared to a loss of $3.9 million in full-year 2025.
• A reduction in cash usage of approximately 50% is expected for full-year 2026 compared to full-year 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging report due to the significant Q4 revenue decline and negative 2026 guidance, despite improvements in full-year Adjusted EBITDA and cash usage.

Positives

• Full-year 2025 revenue increased by 2% to $212.7 million.
• Adjusted EBITDA loss was reduced by 64% to $(3.9) million for full-year 2025, indicating improved operational efficiency.
• Cash usage decreased by 46% to $27.3 million in full-year 2025, demonstrating better cash management.
• Net new active surgeons increased by 202 for full-year 2025, reaching 3,337 active surgeons, a 6% increase.
• The global patent portfolio expanded to 135 granted patents and 199 pending applications, strengthening intellectual property.
• A new credit facility provides an additional $115 million of liquidity, subject to certain conditions.
• Gross margin remained strong at 80.6% in Q4 2025 and 79.8% for full-year 2025.

Negatives

• Fourth quarter 2025 revenue decreased by 9% to $62.5 million compared to the prior year.
• Full-year 2025 net loss increased to $(59.0) million from $(55.7) million in 2024.
• Fourth quarter 2025 net loss significantly widened to $(9.4) million from $(0.5) million in Q4 2024.
• Fourth quarter 2025 Adjusted EBITDA decreased to $6.2 million from $11.1 million in Q4 2024.
• 2026 revenue guidance projects a decline of 6% to 0% compared to full-year 2025.
• 2026 Adjusted EBITDA loss is expected to widen to $4.0 million to $6.0 million from $3.9 million in 2025.
• The decrease in Q4 2025 revenue was primarily driven by a shift in product sales toward lower-priced bunion kits, impacting average selling prices.

Risks

• Challenges in the current market environment, including increased competition.
• Evolving surgeon and patient preferences for minimally invasive bunion solutions.
• Changes in tariff and trade policies.
• Protracted government shutdowns.
• Lower patient demand for elective bunion surgery due to macroeconomic uncertainty or soft consumer sentiment.
• Ability to protect and enforce intellectual property rights, including through patent infringement and unfair competition suits.
• Success in defending against securities class actions and infringement of intellectual property by third parties, including competitors.
• High variability, complexity, and low visibility with respect to items excluded from non-GAAP measures, making forward-looking Adjusted EBITDA reconciliation difficult.

Future Outlook

The company expects continued market share gains and restoration of topline growth in the back half of 2026. Full-year 2026 revenue is guided to be between $200 million and $212 million, representing a decline of 6% to 0% compared to 2025. Adjusted EBITDA loss is projected to be in the range of $4.0 million to $6.0 million for full-year 2026, and cash usage is expected to be reduced by approximately 50% compared to 2025. This guidance reflects continued case volume growth offset by previously disclosed headwinds from demand-driven product and price mix shift within the expanded bunion portfolio.

Management Comments

• "During the fourth quarter, we improved upon the mid-single digit case volume growth that we experienced in the third quarter. This was driven by increasing demand for our comprehensive suite of 3D bunion correction systems by our growing base of over 3,300 surgeon customers."
• "In 2026, we expect our expanded bunion portfolio and forthcoming product launches to deliver continued market share gains and restore topline growth in the back half of the year."

Industry Context

StockSavvy.ai notes that Treace Medical Concepts operates in the competitive medical technology sector, specifically targeting bunion and midfoot deformities. The company's focus on 3D bunion correction systems like Lapiplasty and newer minimally invasive options such as Nanoplasty and Percuplasty positions it within a growing segment seeking advanced surgical solutions. The reported shift towards lower-priced bunion kits and evolving surgeon preferences for minimally invasive solutions reflect broader industry trends where cost-effectiveness and less invasive procedures are gaining traction. The company's expansion of its patent portfolio and digital solutions like IntelliGuide indicates a strategy to maintain a competitive edge through innovation and intellectual property in a market with an estimated 1.1 million annual surgical candidates in the U.S.

Comparison to Industry Standards

• Treace's gross margin of 79.8% for full-year 2025 is robust and generally competitive within the medical device industry, where high margins are common due to specialized products and intellectual property. For example, companies like Stryker (SYK) or Zimmer Biomet (ZBH) often report gross margins in the 60-70% range, indicating Treace's premium pricing or efficient cost of goods sold for its specialized bunion correction systems.
• The 6% increase in active surgeons to 3,337 suggests continued adoption of its systems, which is a positive indicator for market penetration, especially considering the estimated 10,000 U.S. surgeons performing bunion surgery. This growth rate is comparable to successful niche medical device companies expanding their user base.
• The projected 2026 revenue decline of 0-6% contrasts with the typical growth expectations for innovative medical device companies, which often aim for mid-to-high single-digit or even double-digit growth. This decline, attributed to product and price mix shift, suggests a potential challenge in maintaining average selling prices or a strategic shift towards broader market penetration with more accessible products.
• The reduction in cash usage by 46% in 2025 and an expected 50% reduction in 2026 demonstrates a strong focus on operational efficiency and cash management, which is a positive sign for a company still reporting net losses and aiming for profitability.

Legal Proceedings

• Litigation costs of $3.852 million for full-year 2025 and $1.304 million for Q4 2025, primarily related to patent infringement lawsuits.
• The company faces risks related to its success in defending against securities class actions and infringement of its intellectual property by third parties, including competitors.

Stakeholder Impact

• Shareholders: Potential negative impact due to declining revenue guidance and widening net losses, offset by improved cash management and long-term growth strategy.
• Employees: Restructuring costs mentioned in 2024 and 2025 suggest potential impact on workforce, though specific details are limited.
• Customers (Surgeons): Continued increase in active surgeons indicates positive adoption of products, but a shift to lower-priced kits might affect average revenue per surgeon.
• Creditors: A new credit facility provides additional liquidity, which is positive for debt servicing, but continued losses could be a concern.

Next Steps

• Host a conference call on February 27, 2026, at 8:00 a.m. ET to discuss financial results.
• Expand the bunion portfolio and launch forthcoming products in 2026.
• Deliver continued market share gains and restore topline growth in the back half of 2026.
• Leverage investments in its commercial organization and control costs in its organizational structure.
• Expand clinical evidence.
• Protect and enforce intellectual property rights, including through patent infringement and unfair competition suits.

Key Dates

Recommendation

The significant decline in Q4 2025 revenue, coupled with a negative revenue growth outlook for 2026 and an expected widening of Adjusted EBITDA loss, indicates deteriorating financial performance and a challenging near-term future. While cash usage improved, the core business metrics are trending negatively, suggesting that the stock may face downward pressure. The shift to lower-priced products impacting revenue mix is a concerning trend for profitability.

Keywords

Medical Technology, Bunion Correction, Lapiplasty, Adductoplasty, Nanoplasty, Percuplasty, SpeedMTP, Orthopedics, Foot and Ankle Surgery, Medical Devices, SEC Filing, Financial Results, Earnings, TMCI